Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Myelofibrosis treatment in 5 years

Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future of the myelofibrosis space, following the presentation of a plethora of trial updates at the ASH 2021 annual congress. With many Phase III trials underway and an ever-growing pathophysiological understanding, Dr Verstovsek hopes that many new drugs will be made available in the coming years. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Transcript (edited for clarity)

In myelofibrosis in particular, at this ASH, we had so many updates of different clinical trials. The fact is, that we have at least eight Phase III studies underway for possible approval of new drugs in myelofibrosis. So the field is booming. We hope that over the next 3 to 5 years we’ll have many new drugs for our myelofibrosis patients. It’s very exciting, because we are learning about different biological abnormalities in this condition, leading us to test and develop, hopefully to fruition, all these new drugs that can be, perhaps, combined with JAK inhibitors or used after JAK inhibitors, or tackle problems that we have no medications for, like anemia...

In myelofibrosis in particular, at this ASH, we had so many updates of different clinical trials. The fact is, that we have at least eight Phase III studies underway for possible approval of new drugs in myelofibrosis. So the field is booming. We hope that over the next 3 to 5 years we’ll have many new drugs for our myelofibrosis patients. It’s very exciting, because we are learning about different biological abnormalities in this condition, leading us to test and develop, hopefully to fruition, all these new drugs that can be, perhaps, combined with JAK inhibitors or used after JAK inhibitors, or tackle problems that we have no medications for, like anemia. Anemia is a major problem. So I’m looking forward to seeing what’s going to happen, really, and I’m very optimistic to see new drugs developing in the near future.

Read more...